AT ATG+SİKLOSPORİN+ ELTROMPOBAG PROTOKOLÜ

Kaynaklar:

1-Killick, S. B., et al. and the British Society for Standards in Haematology (2016), Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol, 172: 187-207. 

2-Protocol for the treatment of Aplastic Anaemia with Horse Anti-Thymocyte Globulin (hATG, ATGAM® ). Professor J Marsh, and Dr A Kulasekararaj. June 2012. King’s College Hospital NHS Trust.

3-Fenaux P, Ades L. How we treat lower-risk myelodysplastic syndromes. Blood. 2013; 121(21):4280-4286. 

4-Stahl M, Zeidan AM. Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications. Cancer. 2017; 123(10):1703-1713. 

5-Montoro J, Gallur L, Merchan B. Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes. Ann Hematol. 2018; 97(8):1349-1356. 

6-Komrokji RS, Kulasekararaj A, Al Ali NH. Autoimmune diseases and myelodysplastic syndromes. Am J Hematol. 2016; 91(5):E280-E283. 

7-Young NS. Aplastic Anemia. N Engl J Med. 2018; 379(17):1643-1656. Google Scholar Olnes MJ, Sloand EM. Targeting immune dysregulation in myelodysplastic syn dromes. JAMA. 2011; 305(8):814-819. 

8-Stahl M, DeVeaux M, de Witte T, Neukirchen J. The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. Blood Adv. 2018; 2(14):1765-1772. 

9-Xiao L, Qi Z, Qiusheng C. The use of selective immunosuppressive therapy on myelodysplastic syndromes in targeted populations results in good response rates and avoids treatment-related disease progression. Am J Hematol. 2012; 87(1):26-31. 

10-Molldrem JJ, Caples M, Mavroudis D. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol. 1997; 99(3):699-705. PubMed

11-Komrokji RS, Mailloux AW, Chen DT. A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction. Haematologica. 2014; 99(7):1176-1183. 

12-Kadia TM, Borthakur G, Garcia-Manero G. Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. Br J Haematol. 2012; 157(3):312-320. 

13-Passweg JR, Giagounidis AA, Simcock M. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99. J Clin Oncol. 2011; 29(3):303-309.